The PMD-OPTION study enrolled a total of 29 PMD patients across nine expert sites in Germany, Italy and The Netherlands. Its results demonstrate OMT-28’s therapeutic potential to improve the physical condition in PMD based on significant recovery of impaired mitochondrial fitness in the responding patients. The study further underscored the excellent safety and tolerability profile of OMT-28, which has now been evaluated in more than 220 individuals. OMEICOS is preparing for a potentially pivotal Phase IIb/III study in PMD patients with myopathy and/or cardiomyopathy across EU and US sites and expects to initiate this study later this year.
PMD represents a heterogeneous group of conditions. Patients suffer from debilitating and life-threatening health consequences, such as severely limited physical stamina and disease-related changes in the heart and skeletal muscles, as well as associated neurological disorders. By targeting the GPCR-receptor S1PR1 and activating SIRT1/SIRT3, OMT-28 combines immunomodulation with mitochondrial protection – a dual mechanism to tackle inflammation and energy deficits in primary mitochondrial diseases.
OMEICOS Therapeutics is a Berlin-based clinical-stage biopharmaceutical company developing first-in-class small molecule therapeutics for mitochondrial and inflammatory disorders. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts.
OMEICOS is a spin-off from the Max Delbrück Center. As the Max Delbrück Center’s technology transfer partner, Ascenion has accompanied the project from the outset and holds equity in the company.
Further information: OMEICOS’ press release
